Sonal Patel, MD
Family Medicine · Mansfield, MANPI 1336344357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,037, more than ten times the $269 reported in 2023. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$928
- AstraZeneca$684
- Amgen$612
- GSK$471
- UCB, Inc.$458
- AbbVie$397
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,59497%
- Education$1693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 22 | $928 |
| AstraZeneca | 22 | $684 |
| Amgen | 26 | $612 |
| GSK | 36 | $471 |
| UCB, Inc. | 20 | $458 |
| AbbVie | 17 | $397 |
| Abbott | 3 | $316 |
| Novo Nordisk | 12 | $282 |
| Pfizer | 13 | $274 |
| Lilly USA, LLC | 9 | $228 |
| E.r. Squibb & Sons, L.L.C. | 8 | $187 |
| Cequr Corporation | 1 | $144 |
| Novartis | 6 | $111 |
| Boehringer Ingelheim | 4 | $109 |
| Vivus LLC | 1 | $79 |
| Radius Health, Inc. | 3 | $67 |
| Exact Sciences | 3 | $62 |
| Sobi, Inc | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Fresenius Kabi USA, LLC | 2 | $47 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Sandoz | 1 | $35 |
| Dexcom, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Coopersurgical, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Organon | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$299
- CeQur Simplicity$144
- FARXIGA$135
- EVENITY$116
How this compares
$5,763 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $51,181 |
| JardianceEmpagliflozin | 30 | $37,384 |
| TrulicityDulaglutide | 28 | $34,404 |
| FarxigaDapagliflozin Propanediol | 18 | $22,101 |
| JanuviaSitagliptin Phosphate | 13 | $17,606 |
| MounjaroTirzepatide | 12 | $16,195 |
| OzempicSemaglutide | 13 | $13,707 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,078 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $11,939 |
| XareltoRivaroxaban | 12 | $9,890 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,975 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $7,588 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,871 |
| Atorvastatin Calcium | 299 | $3,434 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $274 | $51,18140 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $228 | $50,59940 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $109 | $46,35947 claims |
| GSKBreo Ellipta, Anoro Ellipta, Arnuity Ellipta | $471 | $27,88765 claims |
| AstraZenecaFarxiga | $684 | $22,10118 claims |
| Novo NordiskOzempic | $282 | $13,70713 claims |
| Johnson & JohnsonXarelto | $928 | $9,89012 claims |
| AbbVieSynthroid | $397 | $1,24220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Mansfield
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Sanjeev SharmaFramingham$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.